Literature DB >> 15708547

The delta32 allele distribution of the CCR5 gene and its relationship with certain cancers in a Turkish population.

Naci Degerli1, Emire Yilmaz, Fevzi Bardakci.   

Abstract

OBJECTIVE: In the present study, we determined the frequency of delta32 allele distribution and its relationship with various carcinomas in a Turkish population. DESIGN AND METHODS: We determined the allelic frequency of CCR5-delta32 in 267 healthy individuals as well as 39 breast, 34 laryngeal, 30 thyroid and 20 brain carcinomas in a Turkish population using polymerase chain reaction (PCR).
RESULTS: The frequency of mutant delta32 alleles in the Turkish population was 2.18%. The population was in the Hardy-Weinberg equilibrium. The frequency of the mutant allele was the highest in patients with breast carcinoma (3.85%) among all the carcinomas studied, but there was no statistically significant relationship (P = 0.334).
CONCLUSION: The frequency of the delta32 allele detected in the Turkish population was slightly lower in comparison with the previous reports. The frequency of heterozygote genotypes remained an independent risk factor for the development of breast cancer (odd ratio = 1.628; confidence intervals = 0.442-5.992) as well as other cancers examined in this study.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15708547     DOI: 10.1016/j.clinbiochem.2004.11.001

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  9 in total

1.  CCL5-403, CCR5-59029, and Delta32 polymorphisms and cancer risk: a meta-analysis based on 20,625 subjects.

Authors:  Houqun Ying; Jie Wang; Xueren Gao
Journal:  Tumour Biol       Date:  2014-04-01

2.  Association analysis and allelic distribution of deletion in CC chemokine receptor 5 gene (CCR5Δ32) among breast cancer patients of Pakistan.

Authors:  Faria Fatima; Saima Saleem; Abdul Hameed; Ghulam Haider; Syed Aqib Ali Zaidi; Madiha Kanwal; Sitwat Zehra; Abid Azhar
Journal:  Mol Biol Rep       Date:  2019-03-08       Impact factor: 2.316

Review 3.  CCR2-V64I genetic polymorphism: a possible involvement in HER2+ breast cancer.

Authors:  Bruna Karina Banin-Hirata; Roberta Losi-Guembarovski; Julie Massayo Maeda Oda; Carlos Eduardo Coral de Oliveira; Clodoaldo Zago Campos; Tânia Longo Mazzuco; Sueli Donizete Borelli; Jesus Roberto Ceribelli; Maria Angelica Ehara Watanabe
Journal:  Clin Exp Med       Date:  2015-02-26       Impact factor: 3.984

4.  SDF-1 and CCR5 genes polymorphism in patients with head and neck cancer.

Authors:  Bijan Khademi; Mahboobeh Razmkhah; Nasrollah Erfani; Marjan Gharagozloo; Abbas Ghaderi
Journal:  Pathol Oncol Res       Date:  2008-04-02       Impact factor: 3.201

5.  Individual and combined effect of TP53, MDM2, MDM4, MTHFR, CCR5, and CASP8 gene polymorphisms in lung cancer.

Authors:  Ausra Stumbryte; Zivile Gudleviciene; Gabrielis Kundrotas; Daiva Dabkeviciene; Agne Kunickaite; Saulius Cicenas
Journal:  Oncotarget       Date:  2017-11-29

6.  Absence of Association between CCR5 rs333 Polymorphism and Childhood Acute Lymphoblastic Leukemia.

Authors:  Carlos Eduardo Coral de Oliveira; Marla Karine Amarante; Aparecida de Lourdes Perim; Patricia Midori Murobushi Ozawa; Carlos Hiroki; Glauco Akelinghton Freire Vitiello; Roberta Losi Guembarovski; Maria Angelica Ehara Watanabe
Journal:  Adv Hematol       Date:  2014-04-13

7.  The association between CCR5 Δ32 polymorphism and susceptibility to breast cancer.

Authors:  Junlong Li; Yuan Peng; Hui Liu; Qiang Wu
Journal:  Oncotarget       Date:  2017-08-05

Review 8.  Metabolomics as an Approach to Characterise the Contrasting Roles of CCR5 in the Presence and Absence of Disease.

Authors:  Anandi Rautenbach; Aurelia A Williams
Journal:  Int J Mol Sci       Date:  2020-02-21       Impact factor: 5.923

9.  Evaluating the Association between CCR5delta32 Polymorphism (rs333) and the Risk of Breast Cancer in a Cohort of Iranian Population.

Authors:  Amir Tajbakhsh; Zahra Farjami; Abolfazl Nesaei-Bajestani; Fahimeh Afzaljavan; Mahdi Rivandi; Atefeh Moezzi; Soheila Abedini; Mahla Asghari; Mohammad Mahdi Kooshyar; Fatemeh Homaei Shandiz; Alireza Pasdar
Journal:  Iran J Public Health       Date:  2021-03       Impact factor: 1.429

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.